Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials

INTRODUCTION: Valbenazine is a novel vesicular monoamine transporter 2 inhibitor approved for the treatment of tardive dyskinesia in adults. OBJECTIVE: Using data from double-blind, placebo-controlled trials, analyses were conducted to evaluate the cardiovascular effects of once-daily valbenazine in...

Descripción completa

Detalles Bibliográficos
Autores principales: Thai-Cuarto, Dao, O’Brien, Christopher F., Jimenez, Roland, Liang, Grace S., Burke, Joshua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5878201/
https://www.ncbi.nlm.nih.gov/pubmed/29218680
http://dx.doi.org/10.1007/s40264-017-0623-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5878201/
https://www.ncbi.nlm.nih.gov/pubmed/29218680
http://dx.doi.org/10.1007/s40264-017-0623-1

Ejemplares similares